Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Ash 2021 – Sanofi takes its time with fitusiran
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
Bridgebio sets its heart on besting Pfizer
With phase 3 data approaching, it should soon become clear whether Bridgebio’s amyloidosis project really has an edge over Pfizer’s Vyndaqel.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Ash 2021 preview – small increases and big falls
The early movers could point to a disappointing meeting.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Centessa claims a place in the antitrypsin deficiency pipeline
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Delays hit Sanofi
The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.
